Cetirizine Hydrochloride

FAQ Print

Cetirizine Hydrochloride

by Wikikenko.com

|

Last updated on


  • Chemical Name: (±)-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, dihydrochloride
  • Generic Name: Cetirizine Hydrochloride
  • Chemical Class: Diphenylmethylpiperazine group (second-generation H1 antihistamine)
  • Formulations: Tablets, chewable tablets, oral solution/syrup, extended-release tablets, ophthalmic solution, intravenous injection
  • Brand Names: Zyrtec, Reactine, Aller-Tec, Quzyttir, Zerviate, All Day Allergy, Children’s Zyrtec, Zyrtec-D
  • Manufacturer: Johnson & Johnson, UCB Pharma, Pfizer, Dr. Reddy’s Laboratories, Teva Pharmaceuticals
  • Regulatory Status: Prescription and Over-the-Counter (varies by country); FDA approved; included in WHO Essential Medicines list
  • Origin: Belgium, 1981–1983 (UCB Pharma)

Cetirizine hydrochloride is a widely used second-generation antihistamine that has become a cornerstone in the management of various allergic conditions. Since its introduction to the market in 1987, it has gained popularity for its effectiveness in controlling allergic symptoms while causing fewer sedative side effects compared to first-generation antihistamines.

This comprehensive review examines the pharmacological properties, clinical applications, and safety profile of cetirizine hydrochloride.

Introduction

Cetirizine hydrochloride is an orally active and selective H1-receptor antagonist derived from hydroxyzine, a first-generation antihistamine.

It belongs to the piperazine class of antihistamines and is distinguished by its selective inhibition of peripheral H1 receptors with minimal penetration across the blood-brain barrier. Unlike its predecessor hydroxyzine and other first-generation antihistamines, cetirizine demonstrates reduced sedative effects due to its limited central nervous system (CNS) activity, making it more suitable for daytime use.

The medication was first approved for prescription use in the United States in 1995 and later received over-the-counter (OTC) approval in 2007, reflecting its established safety profile and efficacy. Cetirizine has gained widespread acceptance in the management of allergic conditions such as seasonal and perennial allergic rhinitis, chronic urticaria, and other histamine-mediated disorders.

Chemical Structure

Cetirizine hydrochloride has the chemical name (±)-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, dihydrochloride. Its empirical formula is C21H25ClN2O3·2HCl with a molecular weight of 461.82. The compound is a racemic mixture consisting of levocetirizine (R-enantiomer) and dextrocetirizine (S-enantiomer), with levocetirizine being the pharmacologically active form with greater affinity for H1 receptors.

Structurally, cetirizine contains a chlorophenyl group attached to a piperazine ring, with an ethoxyacetic acid side chain that contributes to its polar nature and limited CNS penetration. Cetirizine hydrochloride is a white, crystalline powder that is highly water-soluble, which contributes to its favorable pharmacokinetic properties and formulation flexibility.

Cetirizine-Based Medicines List

Here are the top eight cetirizine-based medications available in various markets:

  1. Zyrtec – The original brand name product manufactured by Johnson & Johnson, available as tablets, chewable tablets, and syrup
  2. Reactine – A common brand name used in Canada and some European countries, containing cetirizine hydrochloride as the active ingredient
  3. Aller-tec – A generic version of cetirizine commonly found in pharmacies and retail chains in the United States
  4. Zirtek – A brand name used primarily in European markets for cetirizine products
  5. Zyrtec-D – A combination product containing cetirizine and pseudoephedrine, a decongestant, for treating allergic rhinitis with nasal congestion
  6. Zerviate – An ophthalmic formulation of cetirizine hydrochloride (0.24%) used for allergic conjunctivitis
  7. Quzyttir – An intravenous formulation of cetirizine approved for acute urticaria
  8. Zodac – A brand of cetirizine marketed in several countries for treating allergic conditions

Mechanism of Action

Cetirizine works primarily by competitively binding to and blocking histamine H1 receptors, preventing histamine from attaching to these receptors and initiating allergic symptoms. This selective inhibition of H1 receptors affects primarily peripheral tissues rather than the central nervous system, which explains its reduced sedative effects compared to first-generation antihistamines.

The drug’s Ki values for the H1 receptor are approximately 6 nM for the racemic mixture, with the levocetirizine component having a greater binding affinity (3 nM) compared to dextrocetirizine (100 nM).

Beyond its antihistaminic effects, cetirizine demonstrates anti-inflammatory properties independent of H1 receptor antagonism. It suppresses the NF-κB pathway and regulates the release of cytokines and chemokines, thereby modulating inflammatory cell recruitment. Studies have shown that cetirizine inhibits eosinophil chemotaxis and LTB4 release, contributing to its effectiveness in allergic conditions.

Additionally, at higher doses (20 mg), cetirizine has been observed to inhibit the expression of VCAM-1 in patients with atopic dermatitis, further supporting its anti-inflammatory profile. These combined mechanisms explain its clinical effectiveness in managing both the immediate and delayed phases of allergic reactions.

Pharmacokinetics

Absorption

Cetirizine is rapidly and extensively absorbed following oral administration, with an oral bioavailability of at least 70%. Peak plasma concentrations (Cmax) are reached approximately 1 hour after dosing in fasting conditions, with a Cmax of 257 ng/mL following a 10 mg dose and 580 ng/mL after a 20 mg dose.

Food intake delays the time to maximum concentration (Tmax) by about 1.7 hours and decreases Cmax by approximately 23%, but doesn’t significantly affect the overall bioavailability.

Distribution

Cetirizine is highly bound to plasma proteins, with binding rates of 93-96% across a concentration range of 25-1000 ng/mL. The primary binding protein is albumin, with minimal contributions from α1-acid glycoprotein and lipoproteins. The volume of distribution is relatively small, estimated at 0.3-0.45 L/kg, reflecting its limited tissue distribution.

Importantly, cetirizine crosses the blood-brain barrier poorly and slowly, which contributes to its reduced sedative effects compared to first-generation antihistamines. This limited CNS penetration is partly attributed to cetirizine being a substrate for P-glycoprotein, an efflux transporter at the blood-brain barrier.

Metabolism

Unlike many medications, cetirizine undergoes minimal metabolism, with approximately 70% of an administered dose excreted unchanged in the urine. It notably does not undergo significant metabolism by the cytochrome P450 enzyme system, which explains its low potential for drug interactions with medications that inhibit or induce these enzymes.

The limited metabolism that does occur involves oxidation and conjugation pathways, though the specific enzymes responsible have not been fully identified.

Elimination

Cetirizine is primarily eliminated through renal excretion, with 70-85% excreted in urine and 10-13% in feces. About 60% of the cetirizine eliminated in urine is in unchanged form. The elimination half-life ranges from 6.5 to 10 hours in healthy adults, with a mean of approximately 8.3 hours.

This half-life is prolonged in elderly individuals (to 12 hours), in those with hepatic impairment (to 14 hours), and in patients with renal impairment (to 20 hours). The drug’s duration of action is at least 24 hours, allowing for once-daily dosing.

Therapeutic Uses

ConditionFDA Approval StatusTypical DosageComments
Seasonal Allergic RhinitisApprovedAdults & children ≥12 years: 10 mg once daily
Children 6-11 years: 5-10 mg once daily
Children 2-5 years: 2.5 mg once daily
Effective for symptoms like sneezing, rhinorrhea, and watery eyes; approved for ages 2+ years
Perennial Allergic RhinitisApprovedSame as aboveFor year-round allergens such as dust mites, pet dander, and mold; approved for ages 6+ months
Chronic Idiopathic UrticariaApprovedAdults & children ≥12 years: 10 mg once daily
Children 6-11 years: 5-10 mg once daily
Children 6 months-5 years: 2.5 mg once daily
First-line treatment per AAAAI and ACAAI guidelines; higher doses (up to 20 mg) used off-label for severe cases
Allergic ConjunctivitisApproved (ophthalmic)One drop in affected eye(s) twice dailyAvailable as 0.24% ophthalmic solution (Zerviate)
Acute UrticariaApproved (IV formulation)Adults & children ≥12 years: 10 mg IV
Children 6-11 years: 5-10 mg IV
Children 6 months-5 years: 2.5 mg IV
Intravenous formulation (Quzyttir) for acute management
Adjunct in AnaphylaxisOff-labelVariable, typically 10 mg for adultsUsed as adjunct to epinephrine; recommended by AAAAI and ACAAI guidelines
BASCULE SyndromeOff-labelHigh-dose cetirizineUsed for Bier anemic spots, cyanosis, and urticaria-like eruption
Atopic DermatitisOff-labelStandard dosingMay reduce duration and dose of topical anti-inflammatory treatments needed

Side Effects

Cetirizine is generally well-tolerated, but like all medications, it can cause adverse effects. The most common side effects in adults include somnolence (drowsiness), fatigue, dry mouth, pharyngitis, and dizziness. Among second-generation antihistamines, cetirizine is more likely to cause drowsiness than fexofenadine and loratadine, though significantly less so than first-generation antihistamines. The sedative effect appears to be dose-related, with higher doses (20 mg) producing more somnolence than standard doses (10 mg).

In pediatric populations, similar side effects occur, with somnolence, fatigue, and dry mouth being most common. Children are particularly prone to experiencing headaches while taking cetirizine compared to adults. For the ophthalmic solution, the most frequently reported adverse reactions include conjunctival hyperemia and instillation site pain.

Rare but potentially severe adverse events have been reported in postmarketing surveillance, including severe hypotension, anaphylaxis, hemolytic anemia, cholestasis, orofacial dyskinesia, glomerulonephritis, hepatitis, and thrombocytopenia. There have been isolated cases of transient, reversible hepatic transaminase elevations during cetirizine therapy.

A notable adverse effect associated with long-term use of cetirizine is the development of pruritus (generalized itching) upon discontinuation. The FDA has analyzed cases of this withdrawal phenomenon and noted that for some patients, the itchiness was severe enough to impact their ability to work, sleep, or perform daily activities. No specific schedule for tapering cetirizine has been established to prevent this effect.

Drug Interactions

Cetirizine has a relatively favorable drug interaction profile compared to many medications, primarily because it undergoes minimal metabolism by the cytochrome P450 enzyme system. This characteristic reduces the potential for interactions with drugs that are metabolized by or affect these enzymes. However, several significant interactions do exist:

There are 254 known drug interactions with cetirizine, of which 2 are classified as major, 250 as moderate, and 2 as minor. The most significant concern is with substances that cause CNS depression. Cetirizine can potentiate the sedative effects of alcohol, tranquilizers, and other CNS depressants, potentially impairing cognitive and motor functions. Patients should be cautioned about these additive effects and advised to avoid activities requiring mental alertness until they know how cetirizine affects them.

Although cetirizine does not significantly interact with most medications due to its limited metabolism, caution is advised when co-administering it with other medications that can cause drowsiness, such as opioid pain medications, sleep medications, muscle relaxants, and medications for anxiety or depression. These combinations may enhance sedation.

Notably, cetirizine has minimal anticholinergic activity compared to first-generation antihistamines, reducing the risk of anticholinergic-related drug interactions. However, there is one reported case of a child experiencing anticholinergic toxicity after an accidental overdose of cetirizine, suggesting that at very high doses, such effects may be possible.

Safety Considerations

Pregnancy and Lactation

Cetirizine appears to be safe for use during pregnancy, with no evidence of increased risk of congenital malformations or adverse pregnancy outcomes. It is classified as a former FDA pregnancy category B medication. However, first-generation antihistamines like diphenhydramine and doxylamine are generally considered the safest options during pregnancy if an antihistamine is needed.

Regarding breastfeeding, cetirizine is excreted in breast milk, and its use during lactation is generally not recommended. If used, occasional and small doses are considered acceptable, but prolonged use of larger doses may decrease milk supply or cause drowsiness in the infant. For mothers using cetirizine ophthalmic formulation, applying pressure over the tear duct and removing excess solution can minimize the amount reaching breast milk.

Renal and Hepatic Impairment

Dosage adjustments are necessary for patients with renal or hepatic impairment. For those 12 years and older with decreased renal function (creatinine clearance 11-31 mL/min) or on hemodialysis, the recommended dose is reduced to 5 mg daily. Similarly, in patients with hepatic impairment, the dose should be reduced to 5 mg daily for those 12 years and older. These adjustments reflect the altered pharmacokinetics of cetirizine in these populations, with extended elimination half-lives of 14 hours in hepatic impairment and 20 hours in renal impairment.

Pediatric and Elderly Populations

Cetirizine is considered safe for use in children as young as 6 months for perennial allergic rhinitis and chronic urticaria, and for children 2 years and older for seasonal allergic rhinitis. Dosing should be adjusted based on age and weight, with children 6-11 years typically receiving half the adult dose.

In elderly patients, cetirizine should be used with caution as they may be more sensitive to adverse effects, particularly CNS effects. The elimination half-life of cetirizine is prolonged to approximately 12 hours in the elderly compared to 8.3 hours in younger adults.

Overdose

Cetirizine has a wide safety margin, with minimal toxicity even at significantly higher than recommended doses. In animal studies, the minimal lethal dose was approximately 460 times the maximum recommended daily dose for humans. Most cases of overdose, particularly in children, resolve spontaneously with drowsiness being the primary adverse effect. In the rare case of significant overdose, treatment is supportive and symptomatic as there is no specific antidote for cetirizine, and it cannot be effectively removed by dialysis.

Regulatory Status

Cetirizine hydrochloride was patented in 1983 and received FDA approval for prescription use in the United States in 1995. In 2007, the FDA approved cetirizine for over-the-counter (OTC) sale, making it more accessible to consumers. As of 2022, it was the 43rd most commonly prescribed medication in the United States, with more than 13 million prescriptions.

The medication is available in various formulations, including tablets (5, 10, and 20 mg), chewable tablets, extended-release tablets, and syrup (1 mg/mL). The 20 mg strength typically requires a prescription, while the 5 and 10 mg strengths are available OTC in the US. In the UK, up to 30 tablets of 10 mg strength can be purchased without a prescription or pharmacist supervision.

Cetirizine is included in the World Health Organization’s List of Essential Medicines, underscoring its importance in global healthcare systems. In Canada, recent regulatory changes (effective January 21, 2025) have modified the scheduling of cetirizine products for children aged 2-11 years, with package sizes containing no more than 119 mg of cetirizine base now having unscheduled status.

For pediatric use, the FDA has not labeled cetirizine for children under 2 years old for seasonal allergic rhinitis, though it is considered safe for perennial allergic rhinitis and urticaria in children as young as 6 months. This regulatory distinction reflects differing assessments of the benefit-risk profile for different allergic conditions in very young children.

Conclusion

Cetirizine hydrochloride represents a significant advancement in the treatment of allergic conditions, offering effective symptom relief with a reduced risk of sedation compared to first-generation antihistamines. Its favorable pharmacokinetic profile, including once-daily dosing, minimal metabolism, and limited drug interactions, has contributed to its widespread use and availability as an OTC medication in many countries.

While cetirizine may cause drowsiness in some patients, particularly at higher doses, its overall safety profile is excellent, with serious adverse effects being rare. Appropriate dosage adjustments for special populations, including children, the elderly, and those with renal or hepatic impairment, ensure its safe use across diverse patient groups. As a well-established medication with decades of clinical experience and research, cetirizine remains a cornerstone in the management of allergic disorders.


0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted


You might also like